A meta-analysis indicated that median recurrence-free survival for patients with TERT mutations is 14 months, compared to 101 months for those with wild-type TERT. While some cohort studies suggest that TERT promoter mutations are typically not acquired during the process of malignant progression, they may occur independently of the malignant transformation of meningiomas (13). This evidence concerns the gene TERT and meningioma.